Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

News Release

Dr Nazmi Baycin Dubai Emerges as a Global Leader in Aesthetic Medicine Led by Renowned Plastic Surgeon

Rev Up Marketers

Dubai is rapidly solidifying its position as a global capital for aesthetic medicine, with the city’s thriving plastic surgery sector contributing significantly to both healthcare growth and economic diversification. Central to this rise is Dr. Nazmi Baycin, a leading plastic surgeon with over 25 years of experience and a decade of distinguished practice in Dubai. Recent data shows that Dubai conducted over 50,000 aesthetic procedures in 2023, generating an estimated $2.5 billion in market value. With a projected annual growth rate of 7–10%, the emirate is quickly becoming one of the world’s most sought-after destinations for cosmetic and elective medical tourism. Dr. Baycin is recognized for his expertise in procedures such as breast augmentation, female genital surgery, tummy tucks, and chin reshaping. His patient-centered approach, paired with advanced technologies and an artistic eye, has set new benchmarks in aesthetic surgery standards across the region. “Dubai offers an unparalleled combination of clinical excellence, privacy, and cultural accessibility,” said Dr. Baycin. “These qualities continue to attract a growing number of patients, particularly from the Gulf Cooperation Council (GCC) region.” A recent report According to the Dubai Health Authority, more than 691,000 medical tourists visited the emirate in 2023, with nearly half arriving specifically for cosmetic treatments. This influx contributed around AED 1 billion ($280 million) directly to the healthcare sector, and an estimated AED 2.3 billion in indirect revenue across hospitality, real estate, transportation, and wellness services. Dubai’s emergence as a plastic surgery hub is supported by strategic initiatives such as the Dubai Economic Agenda (D33), which aims to double the city’s GDP and enhance its reputation as a global innovation and investment hub. Medical tourism plays a central role in this strategy, with plastic surgery leading the charge. The city’s specialized medical zones—such as Dubai Healthcare City —offer cutting-edge infrastructure, favorable tax conditions, and strong regulatory frameworks, attracting both top-tier talent and international patients. The integration of AI diagnostics, robotic-assisted surgeries, and 3D imaging technology ensures precision, safety, and minimal downtime for patients. Social media has also played a pivotal role in shaping regional aesthetic preferences. Dr. Baycin notes a significant increase in demand for natural-looking, minimally invasive enhancements, particularly among patients from Saudi Arabia, Kuwait, and across the Gulf. “As cultural norms evolve and beauty standards become more globally influenced, personalized aesthetic procedures are gaining popularity,” added Dr. Baycin. “Dubai is meeting that demand with world-class solutions.” With robust government support, advanced medical infrastructure, and a growing influx of high-net-worth individuals seeking discreet care, Dubai is on track to become the global epicenter of aesthetic medicine in the coming decade. About Nazmi Baycin Clinic Nazmi Baycin Clinic is a premier aesthetic surgery practice based in Dubai, led by internationally acclaimed plastic surgeon Dr. Nazmi Baycin. With over 25 years of global surgical experience and more than a decade serving clients in the UAE, the clinic is renowned for delivering advanced, patient-focused cosmetic procedures. Specializing in breast augmentation, female genital surgery, tummy tucks, and facial enhancements, Dr. Baycin combines medical precision with artistic sensibility to provide natural, personalized results. Situated in the heart of Dubai’s medical district, the clinic caters to a diverse international clientele, offering world-class care, discretion, and cutting-edge surgical technologies. For more information, visit www.nazmibaycin.com. Contact Details Nazmi Baycin Dr. Nazmi Baycin info@nazmibaycin.com Company Website https://www.nazmibaycin.com

July 01, 2025 05:30 PM Eastern Daylight Time

ALLIES OF SKIN PARTNERS WITH MINDFULNESS EXPERT AND BEST-SELLING AUTHOR CASE KENNY FOR “SKINCARE = SELF-CARE” CAMPAIGN

Allies of Skin

Allies of Skin, the supercharged clinical skincare brand founded by Nicolas Travis, announces its partnership with mindfulness expert and best-selling author Case Kenny to celebrate the connection between skincare and self-care. Renowned for its results-driven routines, personally curated by Nicolas Travis from the brand’s assortment of supercharged clinical skincare, Allies of Skin is taking skincare one step further. Together with Case Kenny, they introduce a powerful perspective: skincare as self-affirmation. Allies of Skin's iconic routines are sealed with a bespoke affirmation created by Case Kenny – restoring the skin while reconnecting you with your sense of self. The collaboration invites consumers to turn their daily regimens into powerful acts of self-connection, blending high-performance formulas with holistic wellness. Affirmations aren’t just an add-on – they're the final, essential step in any skincare routine. Just as an Allies of Skin product seals in skincare benefits, a self-affirmation seals in intention. Great skin has the power to make you feel better – more confident, more centered, and more connected to yourself. Together, Nicolas Travis and Case Kenny are lighting both the inner and outer light for consumers, redefining skincare as a ritual for total well-being. For the collaboration and as an official #ALLIESPartner, Case Kenny will curate bespoke digital affirmation cards which will be available through social “drops,” lead engaging social content centered around mindfulness, skincare, and self-love, host events aimed at building conscious community, and participate in a co-branded influencer seeding to spread the message that skincare equals self-care. FROM THE FOUNDER "It has taken 18 years for me to appreciate the beauty of the scars from my experience with facial necrosis. Through my own healing journey, I discovered Case Kenny and his brilliant work. His words resonate with me on a soul level, and they serve as guiding light on dark days. It is this light that I hope to share with our allies. The unwavering light that comes with being at home in your skin. The light that radiates from within when you are at peace with yourself and your journey. The light that no person or situation can diminish. It’s time for all of us to shine a little brighter," says Nicolas Travis, Founder of Allies of Skin. FROM CASE KENNY "I’m very excited to partner with Allies of Skin because we share the same belief: the light you carry comes from what you’ve healed. I believe the darkness you endure in life only makes your light shine brighter, and Allies of Skin believes the same. They believe that skincare isn’t just about how you look, but how you feel. That how you care for yourself on the outside is a reflection of the self-respect, growth, and peace you’re building within. That your outer glow is a mirror of your inner work. What I love most is their mission to make skincare more human - to honor the ups and downs, to embrace the imperfections, and to remind us that showing up for yourself is enough. That kind of alignment is meaningful," says Case Kenny. To stay updated on drops, events, and inspiration, follow @alliesofskin and @casekenny on Instagram. ABOUT ALLIES OF SKIN Allies of Skin redefines skincare with a “supercharged clinical” approach, maximizing clinically proven actives, protective antioxidants, and supporting the skin barrier. Founded by Nicolas Travis in 2016, the high-performance formulas deliver visible, transformative results in fewer steps, with innovative active ingredients like Epidermal Growth Factors (GF), Copper Tripeptide, and patented Encapsulated Retinaldehyde (Retinal), with the mission of delivering unparalleled skin regeneration and longevity. Contact Details OGAKI Digital Hallie Sawyer +1 818-388-7338 hsawyer@ogakidigital.com Company Website https://us.allies.shop/

July 01, 2025 05:24 PM Eastern Daylight Time

Former Oura CEO, Harpreet Singh Rai, Joins Loop to Accelerate Preventive Health Innovation

Loop

Loop, the insurance and healthcare company on a mission to add 20 healthy years to the lives of working Indians, has announced that Harpreet Singh Rai, former CEO of health-tracking pioneer Oura and an early investor in Loop, has joined Loop as President, Healthcare. Harpreet brings a decade of experience in building and scaling preventive health solutions that merge science, data, and human behavior. As CEO of Oura from 2018 to 2021, he led the launch of the company’s 2nd and 3rd generation rings, selling over 1 million units. In his new role, Harpreet will lead the development of Loop’s healthcare products, working closely with Loop’s medical, product, and engineering teams. His focus will be on creating seamless, engaging experiences that help people take charge of their health. “India's workforce loses 20 years compared to global peers; not because of destiny, but because our system profits from sickness rather than health. Harpreet has built consumer health products that people actually use and love. That's exactly the leadership we need to scale prevention beyond corporate walls,” said Mayank Kale, Co-founder and CEO at Loop. Before Oura, Harpreet spent nine years as a technology portfolio manager at Eminence Capital, focusing on healthcare and technology investments. He began his career in Morgan Stanley’s M&A group and holds a degree in electrical engineering from the University of Michigan. His rare blend of engineering, investing, and health leadership uniquely equips him to accelerate Loop’s prevention-first approach. “Loop is building something fundamentally different—Mayank and the team have a unique lens to improve healthcare for India. I’m excited to help make healthcare more accessible, engaging, and measurable for millions of working Indians. This is how we add decades to lives—one person, one family, one company at a time,” said Harpreet Singh Rai. About Loop Loop is on a mission to add 20 healthy years to the Indian workforce. By combining best-in-class insurance with unlimited primary care and data-led prevention, Loop empowers over 850,000 employees at 1,200+ companies to live longer, healthier lives. Backed by global investors including Y Combinator, Khosla Ventures, Elevation Capital, and General Catalyst, Loop is redefining corporate healthcare by making prevention profitable, outcomes measurable, and vibrant health possible for every team in India. Contact Details Aditya +91 88607 36808 Aditya.dwivedi09@gmail.com Company Website https://www.loophealth.com/

June 27, 2025 10:00 AM Eastern Daylight Time

Back to the Doctor’s Office: As Telehealth Declines, Demand for In-Person Care Drives a Medical Real Estate Shift

The Hoyt Organization

In the wake of the COVID-19 pandemic, virtual healthcare saw a historic surge. But now, a new trend is emerging: patients are returning to their doctors' offices — and they’re doing it in droves. According to new data from the Center for Telehealth and e-Health Law (CTeL), telehealth use has entered a steady decline since its peak during the pandemic. With the expiration of emergency policies that once expanded access to virtual care, analysts project a staggering 12 million telehealth appointments will be lost annually. This shift is placing renewed importance on brick-and-mortar medical practices—and driving an urgent need for physical medical office space in urban hubs across the country. “This isn’t just a statistical dip — it’s a fundamental shift,” says Kurt Hackett, Vice President of Asset Management at Rethink Capital, which owns and manages the Medical Pavilion at 939 Ellis Street in San Francisco. “We're seeing patients of all types of medical disciplines re-emphasize the value of in-person care, and providers are responding by ramping up their physical presence.” A Premier Option in San Francisco's Healthcare Corridor At the heart of the resurgence of in-person care is the Medical Pavilion at 939 Ellis Street, a premier medical office building situated in San Francisco’s vibrant healthcare corridor along Van Ness Avenue. Nestled close by Sutter Health’s CPMC Van Ness Campus, the Pavilion offers a strategic, central location for healthcare providers looking to expand or relocate to a high-demand urban market. “939 Ellis Street is perfectly positioned for providers who need immediate access to hospital systems, public transit, and city and suburban population,” says Hackett. “It checks all the boxes for modern medical delivery.” The property features: Proximity to top-tier health systems and medical campuses Full and partial floor suites to accommodate a wide range of medical uses Infrastructure designed to meet today’s clinical and compliance needs On-site parking, and mass transit accessibility What’s Driving the In-Person Comeback? Several factors are contributing to the retreat from telehealth and the renewed interest in physical appointments: Clinical Limitations of Virtual Care: While video consultations offer convenience, many conditions — such as orthopedic and cardiac issues, cancer care, and urological disorders — require physical examinations, lab work, and imaging that simply cannot be done remotely. Insurance Reimbursement Reversions: As emergency-era policies sunset, insurers are reverting to pre-COVID reimbursement models which often favor in-person visits. This reimbursement structure creates an incentive for providers to bring patients back into the office. Digital Fatigue: After years of Zoom meetings, online learning, and virtual appointments, both patients and providers are reporting burnout with screen-based interactions. Trust and Patient Experience: Research continues to show that face-to-face care fosters stronger patient-provider relationships and improves long-term treatment outcomes—something digital platforms have struggled to replicate. Investment Strategies Follow the Trend For real estate investors and healthcare providers alike, the shift back to in-person care is shaping portfolio decisions in key metro markets like San Francisco, where aging medical stock and strong population density make modern medical offices particularly attractive. “Providers are increasingly seeking newer, well-located facilities that reflect the current standards of care,” Hackett explains. “Our goal at the Medical Pavilion is to offer not just square footage, but an ecosystem where quality care can thrive.” A New Era of Care Delivery As the pendulum swings away from virtual-first healthcare, the demand for high-quality, strategically located medical office space is expected to grow — particularly in regions like the Bay Area, where healthcare innovation and patient demand continue to intersect. For providers seeking to adapt and grow in this changing environment, properties like the Medical Pavilion at 939 Ellis Street represent a unique opportunity: the chance to be part of San Francisco’s healthcare future, right in the heart of its medical corridor. For leasing inquiries at 939 Ellis St., contact Trask Leonard, president and CEO of Bayside Realty Partners at tleonard@baysiderp.com. About Medical Pavilion at 939 Ellis Street: Positioned in the Van Ness medical hub, Medical Pavilion at 939 Ellis Street is a purpose-built medical office building offering flexible, large-scale space options for healthcare users, with direct access to public transit, nearby hospitals, and the city’s primary healthcare corridor. It can accommodate a range of specialties. It boasts a scenic rooftop terrace and available parking. Contact Details Leeza Hoyt +1 310-343-3197 llhoyt@hoytorg.com Company Website https://939-ellis.com/

June 26, 2025 08:00 AM Pacific Daylight Time

NeuroSense Inches Closer to Pharma Partnership as Canadian Regulatory Progress Turns Heads

The Finance Herald

NeuroSense Therapeutics (NASDAQ: NRSN)* has completed a key pre-submission meeting with Health Canada for its ALS drug PrimeC, signaling potential upcoming eligibility for Canada’s fast-track approval pathway (NOC/c). The positive tone reported from the meeting could signal accelerated Canadian approval coming soon and could also potentially advance negotiations for the partnership with a global pharma player. With strong Phase 2b data and a potential $100–150M of peak revenue from Canadian market alone, this milestone could be a catalyst for regulatory momentum and investor revaluation. ‎ NeuroSense Therapeutics (NASDAQ: NRSN) may be nearing a turning point in its ALS drug development journey, and the market is starting to take notice. The Israeli biotech just disclosed that it held a pivotal pre-submission meeting with Health Canada for PrimeC, its lead ALS candidate, potentially setting the stage for both early approval and the finalization of a major pharma partnership. In a Form 6-K filed with the SEC, NeuroSense confirmed the completion of a pre-New Drug Submission (pre-NDS) meeting with regulators to explore eligibility for Canada’s fast-track approval mechanism, known as the Notice of Compliance with Conditions (NOC/c). The company described the discussion as “constructive” and left the meeting “highly encouraged”, language that signals regulatory alignment and opens the door for PrimeC to potentially Canadian patients much sooner than expected. For ALS patients in Canada—and a company with a current ~$52 million valuationm that kind of timeline could prove transformational. But the Health Canada development is more than just a regulatory checkpoint—it’s a potential trigger for something bigger. Back in December 2024, NeuroSense signed a binding term sheet with a global pharmaceutical company, covering full Phase 3 funding, upfront cash, milestone payments, and double-digit royalties. A positive signal from Canadian authorities could be the validation needed to cement that deal and set the stage for global expansion. PrimeC already has data to back up its ambitions. In its Phase 2b PARADIGM trial, the therapy showed a 36% slowdown in ALS progression and a 43% improvement in survival compelling outcomes in a field where treatment options are few and efficacy gains are hard-won. That performance is part of what’s drawing interest from the industry—and why a Canadian approval could serve as a powerful launchpad, both commercially and strategically. The Canadian ALS market alone could support $100–150 million in annual peak sales, according to company estimates. But what’s arguably more valuable is the opportunity to generate real-world data and establish market traction ahead of broader approvals, particularly in the U.S. and Europe. Investors likely won’t have to wait long for clarity. NeuroSense expects to receive official meeting minutes from Health Canada shortly and will update the market once eligibility is confirmed. If successful, the NDS filing and Phase 3 launch would likely follow. In a sector defined by long timelines and uncertain outcomes, NeuroSense now finds itself in a rare position, with validated clinical data, regulatory momentum, and a pending global partnership that could reprice the story entirely. The next few months may determine whether PrimeC becomes not only a commercial product, but also a cornerstone of a much larger biotech success. ‎ Read more from the Finance Herald The New Digital Iron Curtain: How the EU’s Digital Services Act Threatens American Free Speech The Nobel Dilemma: Should Trump Embrace or Reject a Controversial Legacy? New York City’s Political Revolution: Zohran Mamdani’s Far-Left Vision Sparks National Debate States Challenge Trump Administration’s Funding Cuts in Major Legal Battle Heating Up: Power Crisis Strikes the Eastern U.S. Amid Record Temperatures ‎ ‎ * ⚠︎ Paid Advertisement: This content is a paid advertisement. Wall Street Wire has received compensation from NeuroSense Therapeutics Ltd. for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available redditwire.com/terms. We are not responsible for any price targets that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. Contact Details ‎ media.globalmarkets@gmail.com

June 26, 2025 09:24 AM Eastern Daylight Time

Image

This $13M Biotech Has $40M in Pentagon Funding – Here’s Why BiomX Could Be Biotech’s Best-Kept Secret

VentureBlock

With 3X Its Market Cap in Military Grants and Analyst Targets of $15-16, This Military-Backed Phage Therapy Pioneer Trades at Just $0.48 (NYSE: PHGE)*, all while their competitor (NYSE: ARMP) trades at over 6X ‎‎ BiomX Inc. (NYSE: PHGE)* presents an unusual situation in biotech: a company trading at just below a $13 million market cap that has secured $40 million in non-dilutive funding from the U.S. Defense Health Agency. This Pentagon backing, administered through the Naval Medical Research Command, has enabled the company to advance its bacteriophage therapies without the typical shareholder dilution that plagues early-stage biotechs. The military’s interest centers on antibiotic-resistant infections emerging from conflict zones. According to BiomX CEO Jonathan Solomon, medical personnel are “seeing soldiers coming out of the Ukraine war with extremely antibiotic-resistant infections.” This real-world crisis has elevated phage therapy, using viruses that naturally kill bacteria, from scientific curiosity to strategic priority. ‎ The Numbers Behind the Story BiomX’s recent Phase 2 DANCE trial results help explain the military’s confidence. The study of 41 patients with diabetic foot osteomyelitis showed: Statistically significant reduction in ulcer size by week 12 (p=0.046) Greater than 40% difference in healing between treatment and placebo groups by week 10 Significant improvement in ulcer depth at week 13 (p=0.048) Significant reduction in ulcer area expansion (p=0.017) No serious adverse events These results matter because diabetic foot infections lead to approximately 160,000 amputations annually in the U.S., creating an $8 billion healthcare burden. The same Staphylococcus aureus bacteria causing these civilian amputations also complicates combat wound care, making BX211 a dual-use technology. ‎ Beyond Military Applications While defense funding validates the technology, BiomX’s commercial opportunity spans multiple indications. The company’s BX004 program for cystic fibrosis demonstrated that 14.3% of patients (3 out of 21) completely cleared chronic Pseudomonas aeruginosa lung infections after 10 days of treatment, compared to 0% in the placebo group. One patient had carried the infection for 35 years before achieving clearance. BiomX estimates addressable markets of $2.5 billion globally for diabetic foot infections and $1.6 billion for cystic fibrosis. The FDA has already granted Fast Track and Orphan Drug designations to BX004, potentially accelerating the regulatory pathway. ‎ The Market Disconnect & Opportunity Current analyst coverage reveals a striking valuation gap. H.C. Wainwright maintains a Buy rating with a $15 price target, while Laidlaw & Company also rates the stock Buy with a $16 target. From recent trading levels around $0.52, these targets represent potential upside of approximately 2,800-2,900%. Laidlaw analyst Yale Jen called the BX211 Phase 2 results “an absolutely positive surprise,” characterizing the asset as “high value and clinically de-risked.” H.C. Wainwright’s assessment emphasizes the program’s advancement toward “important regulatory discussions” with the FDA. The disconnect becomes even more apparent when compared to peers. Armata Pharmaceuticals (NYSE: ARMP), the only other publicly-traded pure-play phage therapy company, trades at approximately $70 million, more than 5X BiomX’s valuation despite having just one clinical program compared to BiomX’s two Phase 2 assets and $40 million in military backing. ‎ Understanding the Opportunity Several factors contribute to BiomX's current valuation disconnect: Non-dilutive funding advantage: The $40 million military grant has funded clinical development without issuing new shares, preserving value for existing shareholders. Limited competition: No new drugs have been approved specifically for diabetic foot osteomyelitis in over 20 years, giving BiomX potential first-mover advantage in a massive unmet need. Impressive platform validation: Success in two separate indications (DFO and cystic fibrosis) demonstrates the broader applicability of the phage platform. Near-term catalysts: Phase 2b results for BX004 expected in Q1 2026, FDA meetings for BX211 Phase 2/3 design, and potential additional military funding or partnerships. ‎ The Broader Context BiomX operates within converging megatrends. The Biden administration has proposed $88.2 billion for biodefense over five years, while organizations like DARPA and ARPA-H are investing hundreds of millions in next-generation antimicrobials. NATO has formed a task force specifically to reintroduce phage therapy in military medicine. The company’s ability to address both military and civilian needs positions it uniquely as governments worldwide recognize antimicrobial resistance as a national security threat. With China producing 80-90% of antibiotic raw materials, supply chain vulnerabilities add urgency to developing alternative therapies. ‎ Looking Ahead BiomX’s story combines validated science, government backing, and massive market opportunities with a market cap that appears disconnected from fundamental value. The $40 million in Pentagon funding alone exceeds the company’s current market valuation by 3X, while clinical success and analyst targets suggest significant upside potential. As the company advances toward Phase 2/3 trials for BX211 and awaits Phase 2b results for BX004, the convergence of military necessity and civilian healthcare needs could transform this overlooked biotech into a key player in humanity’s fight against antibiotic-resistant infections. ‎ This article was syndicated from VentureBlock. ‎ ‎ Recent News Highlights BiomX: BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025 BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) ‎ ‎ * ⚠︎ Paid Advertisement Disclaimer: This content is a paid advertisement. Wall Street Wire has received compensation from BiomX Inc. for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available redditwire.com/terms. We are not responsible for any price targets that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. Contact Details ‎ media.globalmarkets@gmail.com

June 26, 2025 08:31 AM Eastern Daylight Time

Image

News Release

NOA Lithium Strikes Critical Water: A Game-Changing Discovery for Rio Grande Project

Global Markets News

In the parched landscapes of Argentina's Lithium Triangle, water is as valuable as the lithium itself. NOA Lithium Brines Inc. (TSXV: NOAL) (OTCPK: NLIBF) has just announced a discovery that could dramatically accelerate the development timeline of its flagship Rio Grande Project—fresh water. The company revealed today that it has successfully located an on-site fresh water source within its 100%-owned Rio Grande Project boundaries, marking a pivotal milestone in the project's advancement toward production. Why This Water Discovery Matters For lithium brine projects, access to industrial water is a make-or-break factor. In the arid regions where lithium salars are typically found, securing water rights and sources can be challenging, expensive, and time-consuming. By discovering this resource on its own property, NOA has eliminated a significant hurdle in the development pathway. "This marks another significant milestone in the advancement of the Rio Grande Project," stated Gabriel Rubacha, NOA's Chief Executive Officer. "Not only have we discovered a fresh water source on-site and within our properties, but its location aligns perfectly with the area of highest lithium concentration and our preliminary assessment for locating a production facility and evaporation ponds." The strategic positioning of this water well, drilled to a depth of 190 meters in the northern section of the project, couldn't be more advantageous. It's situated close to the areas where NOA has identified the highest concentration of lithium and porosity to date—precisely where the company envisions developing future production facilities and evaporation ponds. A Series of Strategic Wins This water discovery adds to NOA's impressive streak of achievements over the past year. The company has methodically checked off critical boxes in its development roadmap: The water well represents one of three fresh water targets identified at Rio Grande, suggesting further potential for expanded water resources as development continues. Positioned in the Heart of the Lithium Triangle NOA's strategic position in Argentina's Lithium Triangle gives it proximity to some of the world's highest-grade, lowest-cost lithium operations. The company has assembled one of the largest lithium brine claim portfolios in the region not owned by a producing company, with over 140,000 hectares across three prospective salars: Rio Grande, Arizaro, and Salinas Grandes. This vast land package in Salta Province—widely recognized as one of Argentina's most mining-friendly jurisdictions—positions NOA alongside industry leaders like Arcadium, Lithium Argentina, Ganfeng, and Rio Tinto. Looking Forward: Accelerating Development With the PEA expected in Q3 2025, NOA is rapidly advancing toward a comprehensive economic evaluation of the Rio Grande Project. The current design contemplates an initial production capacity of approximately 20,000 metric tonnes per year of lithium carbonate equivalent, with scalability to double that capacity through modular expansion. The water discovery adds tangible value to this economic assessment by potentially reducing both capital and operating costs associated with water procurement and transport. As global lithium demand continues to surge, driven by electric vehicle adoption and energy storage requirements, NOA's steady advancement of its Rio Grande Project positions it as an emerging player in the lithium supply chain at precisely the right time. For investors watching the lithium space, NOA's methodical derisking of its flagship project and continued achievement of development milestones make it a compelling story to follow as it progresses toward its goal of becoming Argentina's next major lithium producer. ‎ Recent News Highlights from NOA Lithium: NOA Lithium Discovers Fresh Water at Rio Grande Project NOA Engages Hatch To Lead Preliminary Economic Assessment For Its Rio Grande Project NOA Lithium Advances Towards 2025 Water Exploration at Rio Grande Project Read more about other lithium stocks: NASDAQ: PWM | OTC: LTMCF | NYSE: ALB | NYSE: LAC | OTCQB:NRVTF * Legal Disclaimer & Disclosure - Paid Advertisement: This content is a paid advertisement. Wall Street Wire has received compensation from NOA Lithium Brines Inc. for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available here redditwire.com/terms or in NOA's disclosure's THIS ARTICLE CONTAINS SPONSORED CONTENT PUBLISHED ON BEHALF OF NOA LITHIUM BRINES Contact Details ‎ media.globalmarkets@gmail.com

June 24, 2025 09:18 AM Eastern Daylight Time

News Release

DarioHealth's Platform Solves GLP-1's Biggest Problem, New Research Shows, While Trading at 1% of Hinge Health's $3 Billion Valuation

Global Markets News

DarioHealth Corp. (NASDAQ: DRIO), a digital health innovator in the chronic condition management space, just unveiled significant research findings at the American Diabetes Association Scientific Sessions that could dramatically improve its position in the $100 billion weight loss market. The company's studies demonstrate sustainable outcomes for GLP-1 users even after discontinuing medication - addressing a critical challenge in the industry. The latest findings revealed dramatic improvements in GLP-1 users, with average blood glucose levels dropping from an estimated A1c of 9.0% to 6.7%. Most importantly, users who discontinued GLP-1 medication maintained stable outcomes with no significant weight or glucose rebound for at least six months, according to the company's research. The company's platform leverages artificial intelligence to deliver personalized interventions, with its AI predictive models achieving 89% accuracy in forecasting future glucose levels. These capabilities position DarioHealth to support the growing demand for effective GLP-1 management solutions. Valuation Gap Creates Opportunity With DRIO shares currently trading around $0.69 and a market cap of approximately $30 million, the company appears dramatically undervalued compared to digital health peers. Hinge Health (NYSE: HNGE), which focuses primarily on musculoskeletal care, recently completed its IPO in May 2025 and now trades with a market cap of over $3 billion. This valuation disparity highlights the potential upside for DarioHealth investors. Unlike Hinge Health's focus on musculoskeletal care, DarioHealth offers a multi-condition platform addressing diabetes, hypertension, weight management, and behavioral health. This broader approach provides more comprehensive value to health plans and employers seeking to consolidate digital health vendors. DarioHealth has made strategic moves to strengthen its market position: The company expanded its GLP-1 capabilities through a partnership with MediOrbis, adding prescribing capabilities to enhance its weight management solution It's targeting both employer markets and direct-to-consumer channels The company has built its client base to 97 organizations with a reported 90%+ renewal rate The latest research validates DarioHealth's approach to sustainable weight management. With 44% of large employers now covering obesity drugs according to a Mercer survey, the demand for supportive digital health tools continues to grow. The Financial Picture DarioHealth has been making progress toward improved financial performance. In Q1 2025, the company reported revenue of $6.75 million, a 17% year-over-year increase, with gross margins of 57.5% (70.5% on a non-GAAP basis). Operating expenses decreased 35% compared to the previous year, as the company works toward its stated goal of operational cash flow breakeven by the end of 2025. The Bottom Line As GLP-1 medications continue to reshape weight management approaches, DarioHealth's platform offers a solution to maintain outcomes beyond medication use. The company's comprehensive condition management approach contrasts with more narrowly focused digital health providers like Hinge Health. For investors interested in the digital health sector, DarioHealth may represent an opportunity at current price levels, though it carries the execution risks typical of smaller healthcare technology companies. The significant valuation gap between DarioHealth's $30 million market cap and Hinge Health's $3 billion valuation highlights the potential upside if the company continues to execute on its strategy and build on its latest research findings. ‎ Recent News from Dario: Dario Unveils Groundbreaking GLP-1 and AI-Personalization Digital Health Findings DarioHealth Reports First Quarter 2025 Financial and Operating Results Dario's Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk Populations DarioHealth to Report First Quarter 2025 Results on Wednesday, May 14, 2025 DarioHealth Closes Strategic Refinancing of Existing Debt Facility of up to $50 Million to Provide Additional Operational Flexibility and Support Growth Initiatives ‎ Important Legal Disclaimer & Disclosur e - Paid Advertisement: This content is a paid advertisement. Wall Street Wire has received compensation from DarioHealth Corp. for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available redditwire.com/terms. Contact Details ‎ media.globalmarkets@gmail.com

June 24, 2025 09:07 AM Eastern Daylight Time

Medicus Pharma Ltd. (NASDAQ:MDCX): Novel Treatment For Basal Cell Carcinoma Could Upend The $15 Billion Market

Medicus Pharma Ltd (MDCX)

Skin cancer is the most common form of cancer in the United States, with more than 9,500 cases getting diagnosed every day. In fact, more people are diagnosed with skin cancer each year in the U.S. than all other cancers combined. The most common form of skin cancer is basal cell carcinoma (BCC), which accounts for over 5 million cases of all skin cancers diagnosed in the U.S. each year. Currently, the standard treatment for most BCC patients is surgery, either standard excision or Mohs micrographic surgery, which has led to a significant unmet medical need for a non-surgical option. That is why Medicus Pharma Ltd. (NASDAQ:MDCX), a life sciences company focused on accelerating the clinical development programs of novel therapeutic assets, has been attracting investor attention with its revolutionary new treatment that is under development. A non-invasive novel approach Medicus, through its wholly owned subsidiary SkinJect Inc., is focused on commercializing a novel, non-invasive treatment for basal cell carcinoma using a patented dissolvable microneedle patch. The patch is thumb-sized, and what makes it particularly unique is its ability to deliver a chemotherapeutic agent (doxorubicin) to kill tumor cells on the skin and induce a memory immune response to prevent cancer recurrence. Microneedles are promising devices for painless drug delivery, which can improve the biological effect of drugs through adjustable drug release. This novel non-invasive regimen to treat skin cancer, especially BCC, therefore represents a potentially attractive alternative to surgery and current topical therapeutic options. So far, preliminary trial results have been quite promising. The company completed a Phase I study for SkinJect in March 2021 for participants with superficial and nodular BCC, which met its primary objective of safety and tolerability. In January 2024, a Phase 2 IND clinical protocol was submitted to the FDA for a randomized, controlled, double-blind, multicenter study that began enrollment in August with 60 patients. According to Medicus, an interim analysis of the ongoing clinical study reveals that SKNJCT-003 is trending positively, with a proportion of subjects with complete clinical clearance of more than 60%. In April this year, the company announced that the Institutional Review Board (IRB) had approved an increase in the number of patients from 60 to 90, further highlighting the company’s progress towards validation. The company plans to submit the interim analysis to the FDA as part of a package seeking a Type C meeting with the regulator in Q2 2025 with the aim of seeking approval to fast-track the clinical development program. At the same time, the company has said that it will be expanding the phase 2 clinical study into additional sites in the US from the current nine sites as well as two clinical trial sites in Europe. In addition to that, Medicus has received the study may proceed approval from the UAE Department of Health to commence Phase 2 clinical study (SKNJCT-004) to non-invasively treat BCC. The study is expected to randomize 36 patients in four sites in the UAE. It’s also important to note that the company hasn't limited SkinJect to treating humans only. Last year Medicus received a Minor Use in Major Species Designation (MUMS) for its dissolvable Doxorubin-containing microneedle array (D-MNA) to treat external squamous cell carcinoma (SCC) in horses. MUMS is a designation that is comparable to orphan drug status for human medications. Earlier this month, the company revealed that it had submitted a comprehensive product development plan to treat external SCC under Investigational New Animal Drug, designed to seek concurrence of the FDA under MUMS designation. Significant revenue opportunity As mentioned earlier, the potential addressable market for SkinJect is quite significant. About 40–50% of Americans who live to age 65 will experience BCC or SCC at least once. And while still most prevalent in the older segments of the population, it is becoming ever more frequent in younger individuals. BCC procedures are projected to grow at 4% per annum, reaching 6 million procedures in 2030, representing a market size in excess of $15 billion annually, and Medicus is well positioned to capture a significant share of this market if SkinJect is approved due to a couple of reasons. For starters, it is a less painful, less invasive way to treat skin cancer and also lowers the likelihood of recurrence. Secondly, while Mohs surgery costs range between $2,000 and $15,000, the cost of three SkinJect microneedle patches is estimated at $1,000, illustrating the potential for significant cost savings for patients. Furthermore, SkinJect can be administered the same day as a diagnosis, while the average lead time for surgery in the US spans 2–8 months. Apart from that, the overall incidence of SCC in horses is 2-3%, and recent estimates of the US horse population range from 6.6 to 7.25 million horses. With only a handful of approved oncology drugs in the veterinary market, the company believes that developing a non-invasive treatment for equine SCC represents an untapped and unmet market opportunity potentially in the range of $250 million. Medicus has continued to show its commitment to unlocking more shareholder value with its recent announcement of a binding letter of intent to acquire Antev Ltd. for $75 million in a share exchange transaction. Antev is a clinical-stage biotech company developing Teverelix, a next-generation GnRH antagonist, as the first in-market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate. Collectively, this represents an additional $6 billion in potential market opportunities for Medicus. Antev shareholders will receive an aggregate 19% equity stake in Medicus, plus $65 million in additional contingent payments tied to potential future FDA Phase 2 and New Drug Application approvals. The transaction is expected to close before the end of June. Takeaway Medicus recently announced the closing of its $7 million public offering, which will be used to fund its Phase 2 proof-of-concept clinical trial, further illustrating investor confidence in the company’s progress so far and future prospects. As such, investors searching for a unique opportunity in the cancer treatment space should consider taking a closer look at Medicus before it gains mainstream traction. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by MDCX to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

June 24, 2025 07:00 AM Eastern Daylight Time

1 2 3 4 5 ... 315

Back